Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 533014 | NSE Symbol : SICAGEN | ISIN : INE176J01011 | Industry : Trading |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
29-Jan-2025	07-Feb-2025	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 inter alia to consider and approve the Un-audited Financial Results (both Standalone & Consolidated) of the Company for the Quarter & Nine months ended 31st December 2024. Submission of Unaudited Financial Results (Standalone & Consolidated) of the Company for the Quarter & nine months ended 31st December, 2024. The Board of Directors at its meeting held on 07.02.2025 i.e. today has inter-alia considered and approved the Unaudited Financial Results (Standalone & Consolidated) together with the Limited Review Reports of the Auditors for the Quarter & Nine months ended 31st December, 2024 (As Per Bse Announcement Dated on 07.02.2025)
28-Oct-2024	05-Nov-2024	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2024 inter alia to consider and approve the Un-audited Financial Results (both Standalone & Consolidated) of the Company for the Quarter & half year ended 30th September 2024. The Board of Directors of the Company at its meeting held today has, inter alia, considered and approved the Un-audited Standalone and Consolidated Financial Results of the Company along with the Limited Review Reports of auditors for the quarter and half year ended 30th Sept'' 2024. The copies of the aforesaid Un-audited Financial Results are attached. Out come of Board Meeting dated 05.11.2024 is attached (As per BSE Announcement Dated on 05/11/2024)
30-Jul-2024	07-Aug-2024	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2024 inter alia to consider and approve the Un-audited Financial Results (both Standalone & Consolidated) of the Company for the Quarter ended 30th June 2024. The Board of Directors at its meeting held on today i.e. 07.08.2024 has inter-alia considered and approved the Unaudited Financial Results for the quarter ended 30th June, 2024. Outcome of the Board meeting dated 07.08.2024. (As Per BSE Announcement dated on 07.08.2024)
30-Apr-2024	15-May-2024	Final Dividend	Final Dividend & Audited Results In the meeting of Board of Directors of the Company held on 15.05.2024 i.e. today, the Board has inter alia considered and approved the Audited Financial Results (both Standalone & Consolidated) of the Company for the Quarter and year ended 31st March, 2024 together with the Auditors Report thereon. The Board has also recommended 6% Equity Dividend (60 paise per share) on Equity Capital of the Company for the Financial Year 2023-24. (As Per BSE Announcement Dated on 15.05.2024)
25-Mar-2024	25-Mar-2024	Revision in Directors Remuneration	The Board of Directors in their meeting held on 25th March, 2024 i.e. today, has considered to increase the remuneration payable to Whole Time Director based on recommendation of Nomination & Remuneration Committee and decided to seek shareholders approval through Postal Ballot. Necessary Notice of Postal Ballot will be sent to shareholders in due course of time.
31-Jan-2024	13-Feb-2024	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the unaudited financial results (both Standalone & Consolidated) of the Company for the quarter & nine months ended on 31st December 2023. Unaudited financial results for the quarter and nine months ended 31st December 2023 (As Per BSE Announcement dated on 13.02.2024)
30-Oct-2023	08-Nov-2023	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve the unaudited Financial Results (both Standalone & Consolidated) of the Company for the Quarter & half year ended 30th September 2023. The Board of Directors of the Company at its meeting held on 08th November 2023 has inter alia considered and approved the Un-audited Financial Results (Standalone & Consolidated Results) of the Company for the quarter and half year ended 30th September 2023. Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, copies of the aforesaid financial results together with limited review report of Auditors are attached. (As Per BSE Announcement Dated on 08/11/2023)
31-Jul-2023	10-Aug-2023	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve the unaudited Financial Results (both Standalone & Consolidated) of the Company for the Quarter ended 30th June 2023. This is to inform that the Board of Directors of the Company at its meeting held on 10th August 2023 has inter alia considered and approved the unaudited financial results of the Company for the quarter ended 30th June 2023. Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, copies of the aforesaid financial results together with limited review report of the auditors are enclosed herewith. The above information may kindly be taken on record. (As Per BSE Announcement dated on 10.08.2023)
11-May-2023	22-May-2023	Accounts	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2023 inter alia to consider and approve the Audited Financial Results and Audited Financial Statements for the year ended 31st March 2023 and recommendation of Equity Dividend if any for the FY 2022-23. The Board of Directors at its meeting held on today, has recommended the Dividend for the Financial Year 2022-23 is 6% i.e. (60 paise per share) on the Equity Capital of the Company subject to the approval of shareholders at the ensuing Annual General Meeting. In the meeting of Board of Directors of the Company held on 22.05.2023, i.e. today, the Board has inter alia considered and approved the Audited Financial Results for the quarter & year ended 31.03.2023 together with the Auditors Report thereon. The board has also recommended 6% dividend (.60 paise per share) on Equity Capital of the Company for the financial year 2022-23. (As Per BSE Announcement Dated on 22.05.2023)
31-Jan-2023	09-Feb-2023	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve the unaudited financial results of the Company for the quarter & nine months ended 31 Dec 2022. The Board of Directors, at its meeting held today has inter alia, considered and approved the Unaudited Financial Results of the Company together with Limited Review Report of Auditors for the quarter and nine months ended 31st December 2022. The Board of Directors of the Company at its meeting held today has inter alia considered and appointed Ms. Ankita Jain as Company Secretary & Compliance Officer of the Company with immediate effect. With reference to your e-mails requesting to provide additional details for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015 on submission of unaudited financial results of the Company for the quarter and nine months ended 31st December, 2022, we wish to inform you that the Board Meeting held on 9th February, 2023 was commenced at 11:30 a.m. (IST) & concluded at 12:41 p.m. (IST). (As Per BSE Announcement Dated on 09/02/2023)
21-Oct-2022	01-Nov-2022	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2022 inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September 2022. This is to inform you that the Board of Directors of the company at their meeting today has considered and approved change in directorate of the company and postal ballot. We request you to kindly take the above on record. (As Per BSE Announcement Dated on 01.11.2022)
03-Aug-2022	09-Aug-2022	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2022 inter alia to consider and approve the Unaudited Financial Results for the quarter ended 30th June 2022. The Board of Directors of the Company at its meeting held today, has inter alia considered and approved the Unaudited Financial Results (both standalone and consolidated results) of the Company for the Quarter ended 30 June 2022 together with limited review report issued by the statutory auditors. (As Per BSE Announcement Dated on 09.08.2022)
18-May-2022	25-May-2022	Accounts	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 inter alia to consider and approve the Audited Financial Results and Audited Financial Statements for the year ended 31st March 2022 and recommendation of Equity Dividend if any for the FY 2021-22. The Board of Directors of the Company, at its meeting held today, has recommended equity dividend @ 2.5% (25 paise per share) for the year ended 31 March 2022 and the payment of said equity dividend shall be subject to the approval of shareholders at the ensuing Annual General Meeting of the Company. (As per BSE Announcement Dated on 25/5/2022)
31-Jan-2022	11-Feb-2022	Quarterly Results	SICAGEN INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 inter alia to consider and approve the unaudited financial results of the company for the quarter and nine months ended 31st December 2021. The Board of Directors of the Company at its meeting held on 11.02.2022 has inter alia, considered and approved the unaudited financial results of the Company for the quarter and nine months ended 31st December 2021. Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the aforesaid financial results together with the limited review report of statutory auditors are submitted herewith. The Board of Directors of the Company at its meeting held on 11.02.2022 has inter alia, considered and approved a draft Scheme of Amalgamation of wholly owned subsidiary Company M/s. Danish Steel Cluster Pvt Ltd with M/s. Sicagen India Limited. Pursuant to Regulation 37 of SEBI (LODR) Regulations 2015, a copy of draft Scheme of Amalgamation is submitted herewith. (As Per BSE Announcement dated on 11.02.2022)
02-Nov-2021	10-Nov-2021	Quarterly Results	Quarterly Results The Board of Director of the Company at its meeting held today, has interalia considered and approved the Unaudited Financial Results together with Limited Review Reports issued by the statutory auditors for the quarter/half year ended 30 Sept 2021. Copies of the aforesaid results are submitted herewith. The above results may kindly be taken on record. The Board of Directors of the Company at its meeting held today, has considered and appointed Ms. S. Ankita Sharma as Company Secretary & Compliance Officer of the Company w.e.f. 01st December 2021 as recommended by the Nomination & Remuneration Committee. Ms. S Ankita Sharma, aged about 27 years, is a qualified Company Secretary (ACS) and having 3 years of work experience in corporate secretarial functions. The above information may kindly be taken on record. (As per BSE Announcement Dated on 10/11/2021)

1 2

LOGIN HERE

Sicagen India Ltd

Board Meeting